This work by Srivastava et al. demonstrates targeting NOTCH1 downstream effectors could augment GSI treatments and potentially avoid some of the inherent toxicities and resistances associated with this as a T-ALL therapy. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.